A previously halted gene therapy trial for the treatment of rheumatoid arthritis has been given the green light to resume.
The trial, conducted by Seattle-based Targeted Genetics Corporation,
was shut down this summer after Jolee Mohr, aged 36 years, died 3
weeks after receiving a gene therapy injection to treat inflammatory arthritis. Mohr enrolled in this phase 1/2 trial of a new gene therapy,
which involved injections of an adeno-associated virus vector carrying a gene coding for a protein that inhibits tumor necrosis factor α
(TNF-α), a proinflammatory cytokine. Mohr received an initial injection in her right knee in February and a second in July.
Hampton T. Arthritis Gene Therapy Trial Resumes. JAMA. 2008;299(1):28. doi:10.1001/jama.2007.37
Customize your JAMA Network experience by selecting one or more topics from the list below.